Abstract
Background: A close relationship between rheumatic diseases and cardiovascular disease (CVD) has been reported, accounting for the higher mortality and morbidity observed in these patients. In the last years, it has been clearly reported that patients affected by primary Sjögren’s syndrome (pSS) experienced an increased risk of CVD.
Objective: This review aimed at investigating CVD, traditional cardiovascular (CV) risk factors and possible targeted therapeutic strategies in pSS patients.
Method: Available literature concerning CV risk factors in pSS patients has been selected and discussed.
Conclusion: Disease-related characteristics and traditional CV risk factors contribute to observed atherosclerotic damage in pSS patients. The pro-inflammatory mediators together with hypertension and type 2 diabetes, which are more prevalent in pSS patients, determine the increased CV burden. Future studies are needed to fully elucidate the role of possible targeted therapies.
Keywords: Atherosclerosis, cardiovascular disease, cardiovascular risk, comorbidity, endothelial damage, Sjögren syndrome.
Graphical Abstract
Reviews on Recent Clinical Trials
Title:Cardiovascular Disease in Primary Sjögren’s Syndrome
Volume: 13 Issue: 3
Author(s): Onorina Berardicurti*, Piero Ruscitti, Paola Cipriani, Francesco Ciccia, Vasiliki Liakouli, Giuliana Guggino, Francesco Carubbi, Paola Di Benedetto, Giovanni Triolo and Roberto Giacomelli
Affiliation:
- Division of Rheumatology, University of L`Aquila, L`Aquila,Italy
Keywords: Atherosclerosis, cardiovascular disease, cardiovascular risk, comorbidity, endothelial damage, Sjögren syndrome.
Abstract: Background: A close relationship between rheumatic diseases and cardiovascular disease (CVD) has been reported, accounting for the higher mortality and morbidity observed in these patients. In the last years, it has been clearly reported that patients affected by primary Sjögren’s syndrome (pSS) experienced an increased risk of CVD.
Objective: This review aimed at investigating CVD, traditional cardiovascular (CV) risk factors and possible targeted therapeutic strategies in pSS patients.
Method: Available literature concerning CV risk factors in pSS patients has been selected and discussed.
Conclusion: Disease-related characteristics and traditional CV risk factors contribute to observed atherosclerotic damage in pSS patients. The pro-inflammatory mediators together with hypertension and type 2 diabetes, which are more prevalent in pSS patients, determine the increased CV burden. Future studies are needed to fully elucidate the role of possible targeted therapies.
Export Options
About this article
Cite this article as:
Berardicurti Onorina*, Ruscitti Piero, Cipriani Paola, Ciccia Francesco, Liakouli Vasiliki, Guggino Giuliana, Carubbi Francesco, Di Benedetto Paola, Triolo Giovanni and Giacomelli Roberto, Cardiovascular Disease in Primary Sjögren’s Syndrome, Reviews on Recent Clinical Trials 2018; 13 (3) . https://dx.doi.org/10.2174/1574887113666180315130336
DOI https://dx.doi.org/10.2174/1574887113666180315130336 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma
Recent Patents on Anti-Cancer Drug Discovery Micronized Purified Flavonoid Fraction (MPFF)*: A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency
Current Vascular Pharmacology Fabry Disease and Cardiovascular Involvement
Current Pharmaceutical Design Central Nervous System Circuitry and Peripheral Neural Sympathetic Activity Responsible for Essential Hypertension
Current Neurovascular Research Non-Insulin Dependent Diabetes Mellitus: Present Therapies and New Drug Targets&#
Mini-Reviews in Medicinal Chemistry Serum Adiponectin Levels in Patients with Familial Mediterranean Fever
Protein & Peptide Letters Targeting New Pharmacological Approaches for Alzheimer’s Disease: Potential for Statins and Phosphodiesterase Inhibitors
CNS & Neurological Disorders - Drug Targets Dietary Approaches and Alternative Therapies for Polycystic Ovary Syndrome
Current Nutrition & Food Science Combinations of Renin-Angiotensin-Aldosterone System Antagonists:True Advantages?
Current Pharmaceutical Design Editorial [Hot topic: Crucial Role of Redox Signaling in the Regulation of Heart Health (Guest Editor: Dipak K. Das)]
Current Cardiology Reviews Frailty Among Alzheimer’s Disease Patients
CNS & Neurological Disorders - Drug Targets Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Current Vascular Pharmacology Therapeutic Potential of Phytochemicals in Combination with Drugs for Cardiovascular Disorders
Current Pharmaceutical Design FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment
Current Medicinal Chemistry An Overview of Cardenolides in Digitalis - More Than a Cardiotonic Compound
Current Pharmaceutical Design Therapeutic Effects of Renal Denervation on Renal Failure
Current Neurovascular Research Editorial (Thematic Issue: The (Same Old) Problem of Uncontrolled Hypertension)
Current Hypertension Reviews Preface [Hot topic: Insulin Resistance and Impaired Coronary Endothelial Function (Guest Editor: Teruo Inoue)]
Current Drug Targets - Cardiovascular & Hematological Disorders Exploring Genetic Influences on Cognition: Emerging Strategies for Target Validation and Treatment Optimization
Current Drug Targets - CNS & Neurological Disorders Dual Modulation of Vascular Function by Perivascular Adipose Tissue and Its Potential Correlation with Adiposity/Lipoatrophy-Related Vascular Dysfunction
Current Pharmaceutical Design